Choroidal Melanoma and Vision LossChoroidal melanoma is cancer that affects a part of the eye; choroidal melanomas can cause vision loss. The tumors can also metastasize to other parts of the body, which can be fatal. It’s the most common eye cancer in adults.
Aura Biosciences, a clinical-stage biopharmaceutical company, is developing a new class of tumor-targeted therapies for choroidal melanoma patients. Last week, the company announced the dosing of the first patient in a Phase 2 study evaluating the safety and efficacy of their lead product candidate (AU-011). If successful, their treatment could be the future first-line treatment for patients with the condition.
“I am honored to have enrolled the first subject in this exciting trial of AU-011 that, if approved, may offer patients the first targeted therapy that has the potential to not only control tumors but also to preserve vision in the majority of those treated — which could usher in a very beneficial paradigm shift in the management of this challenging disease,” commented Timothy S. Fuller, M.D. from Texas Retina Associates in Dallas, TX. “In addition, the suprachoroidal injection is a straightforward procedure that ocular oncologists should easily be able to perform.”
If you or someone you love is struggling with vision loss, SDCB may be able to help. Please contact us to learn more about our programs.
Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma